drugset
drugset / Trial / NCT03937999

Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.

NCT03937999 ↗

Phase 4 Terminated 1 enrolled Montefiore Medical Center Merck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This study will examine whether the human monoclonal antibody, bezlotoxumab administered AFTER acute Clostridioides difficile (C.diff) has resolved, but during a period of subsequent antibiotic therapy, will eliminate the high risk of C. diff relapse.

Timeline

Start
2019-08-30
Primary completion
2022-05-15
Completion
2022-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Bezlotoxumab Monoclonal antibody 10 mg/kg Intravenous

Indications

Clostridium difficile colitis